# US 2026/0226026 A1 · Compound as ctps1 inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0226026 A1
- Document ID: US20260226026A1
- Status: Published application
- Kind: A1
- Application number: 19/149,677
- Filed: 2024-01-19
- Published: 2026-08-06
- Earliest claimed: 2023-01-19
- Assignees: Hangzhou Innogate Pharma Co., Ltd.; Innorace Biopharma Co., Ltd.
- Applicants: Hangzhou Innogate Pharma Co., Ltd.; Innorace Biopharma Co., Ltd.
- Inventors: Hancheng ZHANG; Congcong CAI; Shiya ZHU
- Web page: https://patentgrep.com/patent/US20260226026A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61K 31/426: 1,3-Thiazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/497: containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 17/14: for baldness or alopecia
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/04: for myasthenia gravis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07D 277/52: to sulfur atoms, e.g. sulfonamides
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided in the present invention is a class of compounds. Specifically, provided in the present invention is a compound having a struc-ture as shown in formula (1), or an optical isomer, pharmaceutically accept-able salt, prodrug, deuterated derivative, hydrate and solvate thereof. The compound can effectively inhibit CTPS 1, and is used for treating or prevent-ing diseases or disorders associated with the activity or expression quantity of CTPS1.

## Claims

### Claim 1

A compound of formula (I), or an optical isomer, pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate, or solvate thereof:
wherein in formula (I):
A is selected from Formula (Ia), Formula (Ib), or Formula (Ic):
wherein in Formula (Ia), Formula (Ib), and Formula (Ic), “” represents the point which attach to Ar1 in the compound of Formula (I); “” represents the point which attach to B in the compound of Formula (I);
B is —NHC(═O)— or —C(═O)NH—;
Ar1, Ar2 and Ar3 are each independently selected from aryl and heteroaryl;
R is selected from C1-6 alkyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, C3-6 cycloalkyl-C1-4 alkyl, 3- to 6-membered heterocyclyl-C1-4 alkyl, C3-6 cycloalkyl-C2-4alkynyl, 3- to 6-membered heterocyclyl-C2-4alkynyl, and C3-6 cycloalkyl-C(═O)—C1-2 alkyl;
R1 is selected from hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy and CN;
R2 is selected from hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, and CN;
R3 is selected from hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkyl-C1-4 alkyl, C3-6 cycloalkyl-C2-4alkynyl, 3- to 6-membered heterocyclyl, 3- to 6-membered heterocyclyl-C2-4alkynyl, ORa, SRa, NRcRc, CN, or a group of Formula (Ie) (as shown below); wherein Ra is selected from hydrogen, C1-4 alkyl, C1-4 haloalkyl, C3-6 cycloalkyl, or C3-6 cycloalkyl-C1-4 alkyl; each Rc is independently selected from hydrogen, C1-4 alkyl, and C1-4 haloalkyl;
R4 is selected from hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, hydroxy, C1-4 alkoxy, and CN;
R5 is selected from hydrogen, C1-4 alkyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, aryl, and heteroaryl;
M is selected from CRhRi; wherein Rh and Ri are each independently selected from hydrogen, halogen, C1-4 alkyl, C3-6 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, heteroaryl, CN, C(O)Rg, C(O)ORf, or C(O)NRdRd; wherein said alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl are each optionally substituted by one or more substituents independently selected from the group consisting of: halogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, aryl, heteroaryl, CN, ORf, SRf, NRdRd, C(O)Rg, C(O)Of, OC(O)Rg, C(O)NRdRd, NRdC(O)Rg, NRdC(O)NRdRd, OC(O)NRdRd, NRdC(O)ORf, OC(O)ORf, S(O)2NRdRd, NRdS(O)2Rg, and NRdS(O)2NRdRd; or Rh and Ri together with the carbon atom to which they are attached form a 3- to 8-membered cyclic structure, said cyclic structure optionally containing 0, 1, or 2 heteroatoms independently selected from N, O and S, and optionally substituted by one or more substituents independently selected from the group consisting of halogen, C1-4 alkyl, CN, ORf, SRf, NRdRd, and =M, wherein M is as defined above; wherein each Rd is independently selected from hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxyC2-4alkyl, C3-6 cycloalkyl, and 3- to 6-membered heterocyclyl; each Rf is independently selected from hydrogen, C1-4 alkyl, C1-4 haloalkyl, C3-6 cycloalkyl, and 3- to 6-membered heterocyclyl; each Rg is independently selected from hydrogen, C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, aryl, and heteroaryl;
X and Y are each independently selected from O, CReRe and NRb; wherein each Re is independently selected from hydrogen, halogen, C1-4 alkyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, aryl, heteroaryl, CN, ORf, SRf, NRdRd, C(O)Rg, C(O)ORf, OC(O)Rg, C(O)NRdRd, NRdC(O)Rg, NRdC(O)NRdRd, OC(O)NRdRd, NRdC(O)ORf, OC(O)ORf, S(O)2NRdRd, NRdS(O)2Rg and NRdS(O)2NRdRd; Rb is selected from hydrogen, C1-4 alkyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, aryl, heteroaryl, C(O)Rg, C(O)ORf, C(O)NRdRd, S(O)2NRdRd and S(O)2Rg; the alkyl in Re or Rb is optionally substituted by one or more substituents selected from the group consisting of halogen, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, aryl, heteroaryl, CN, ORf, SRf, NRdRd, C(O)Rg, C(O)Of, OC(O)Rg, C(O)NRdRd, NRdC(O)Rg, NRdC(O)NRdRd, OC(O)NRdRd, NRdC(O)ORf, OC(O)ORf, S(O)2NRdRd, NRdS(O)2Rg, and NRdS(O)2NRdRd; Rd, Rf, Rg are defined as above;
provided that when A is formula (Ic) and Y is NRb, then NRb is selected from aryl, heteroaryl, C(O)Rg′, or Formula (Id),
wherein “” represents the point which attach to N in Formula (Id); Rg′ is selected from C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, or 3- to 6-membered heterocyclyl; M′ is selected from O or CRhRi; R4, Rh and Ri are as defined above;
with the proviso that, when A is selected from formula (Ic), Y is selected from O, CReRe, or NRb, and Rb is other than aryl, heteroaryl, C(O)Rg′, and Formula (Id), then R is selected from C3-6 cycloalkyl-C2-4 alkynyl, 3- to 6-membered heterocyclyl C2-4 alkynyl, or C3-6 cycloalkyl C(═O)C1-2 alkyl; or R3 is selected from C3-6 cycloalkyl-C2-4 alkynyl, 3- to 6-membered heterocyclyl C2-4 alkynyl, or formula (Ie);
wherein “” represents the point which attach to Ar3 in Formula (Ie); and Re, Rb, Rg′, M′, and R4 are as defined above;
wherein p1, p2 and p3 are each independently selected from 0, 1, 2 and 3;
each m and each n are independently selected from 0, 1, 2, 3, 4, 5 and 6; provided that m and n are not both 0;
each q is independently selected from 0, 1, 2, 3 and 4;
wherein each of the aforementioned alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, cyclic structure, aryl, and heteroaryl groups is optionally and independently substituted by 1 to 3 substituents independently selected from the group consisting of: halogen, C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl, C2-4 alkynyl, C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, heteroaryl, CN, NO2, ORf, SRf, NRdRd, C(O)Rg, C(O)ORf, C(O)NRdRd, NRdC(O)Rg, NRdS(O)2Rg and S(O)2Rg, provided that the resulting chemical structure is stable and chemically meaningful; wherein Rd, Rf, and Rg are as defined above;
unless otherwise specified, the aforementioned aryl is an aromatic group containing 6 to 12 carbon atoms; heteroaryl is a 5- to 15-membered heteroaromatic group; and cyclic structure is a saturated or unsaturated cyclic group which optionally containing heteroatoms.

### Claim 2 (depends on 1)

The compound of claim 1, characterized in that Formula (I) is Formula (IIa) or Formula (IIb):
wherein the definitions of the groups in Formula (IIa) and Formula (IIb) are as defined in claim 1.

### Claim 3 (depends on 1, 2)

The compound according to any one of claims 1-2, characterized in that Formula (I) is Formula (III):
D, E, and G are each independently selected from N or CR1, provided that no more than two of D, E, and G are N;
U is N or CR2;
V is N or CR3;
R1, R2, R3, and the definitions of the remaining groups in Formula (III) are as defined in claim 1.

### Claim 4 (depends on 1, 2, 3)

The compound according to any one of claims 1-3, characterized in that formula (I) is formula (IVa), formula (IVb), or formula (IVc):
U is N or CH;
the remaining groups in Formula (IVa), Formula (IVb), and Formula (IVc) are as defined in claim 1.

### Claim 5 (depends on 1)

The compound according to claim 1, characterized in that formula (I) is formula (V):
D, E and G are each independently selected from N or CR1, provided that no more than two of D, E, and G are N;
U is N or CR2;
V is N or CR3;
R1, R2, R3, and the remaining groups in Formula (V) are as defined in claim 1.

### Claim 6 (depends on 1, 5)

The compound according to any one of claims 1 and 5, characterized in that Formula (I) is formula (VIa), formula (VIb), or formula (VIc):
U is N or CH;
the remaining groups in Formula (VIa), Formula (VIb), and Formula (VIc) are as defined in claim 1.

### Claim 7 (depends on 1)

The compound according to claim 1, characterized in that formula (I) is formula (VII):
the remaining groups in formula (VII) and provisos are as defined in claim 1.

### Claim 8 (depends on 1, 7)

The compound according to claim 1 or 7, characterized in that formula (I) is formula (VIII):
D, E and G are each independently selected from N or CR1, provided that no more than two of D, E, and G are N;
U is N or CR2;
V is N or CR3;
R1, R2, R3, and the remaining groups in Formula (VIII) are as defined in claim 1.

### Claim 9 (depends on 1, 7, 8)

The compound according to any one of claims 1 and 7-8, characterized in that formula (I) is formula (IXa), formula (IXb), formula (IXc):
U is N or CH;
the remaining groups in Formula (IXa), Formula (IXb), and Formula (IXc) and the provisos are as defined in claim 1.

### Claim 10 (depends on 1, 2)

The compound according to any one of claims 1-2, characterized in that Formula (I) is Formula (Xa) or Formula (Xb):
D, E, and G are each independently selected from N or CH, provided that no more than two of D, E, and G are N;
M is selected from CRhRi; wherein Rh and Ri are each independently selected from hydrogen, halogen, C1-4 alkyl, C3-6 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, heteroaryl, CN, C(O)Rg, C(O)ORf, or C(O)NRdRd; wherein said alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl are each optionally substituted by one or more substituents independently selected from the group consisting of halogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, aryl, heteroaryl, CN, ORf, SR, NRdRd, C(O)Rg, C(O)Of, OC(O)Rg, C(O)NRdRd, NRdC(O)Rg, NRdC(O)NRdRd, OC(O)NRdRd, NRdC(O)ORf, OC(O)ORf, S(O)2NRdRd, NRdS(O)2Rg and NRdS(O)2NRdRd; or
Rh and Ri, together with the carbon atom to which they are attached, form a 3- to 8-membered cyclic structure, said cyclic structure optionally containing 0, 1 or 2 heteroatoms independently selected from N, O and S, and optionally substituted by one or more substituents independently selected from the group consisting of: halogen, C1-4 alkyl, CN, ORf, SRf, NRdRd and =M, wherein M is as defined above;
each Rd is independently selected from hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy-C2-4 alkyl, C3-6 cycloalkyl, or 3- to 6-membered heterocyclyl; each Rf is independently selected from hydrogen, C1-4 alkyl, C1-4 haloalkyl, C3-6 cycloalkyl, or 3- to 6-membered heterocyclyl; each Rg is independently selected from hydrogen, C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, aryl, or heteroaryl;
m and n are each independently selected from 0, 1, 2, 3, 4, 5, or 6.

### Claim 11 (depends on 1, 2, 9)

The compound according to any one of claims 1-2 and 9, characterized in that formula (I) is formula (XIa), formula (XIb), formula (XIc), formula (XId), formula (XIe), or formula (XIf):
wherein M is selected from CRhRi; wherein Rh and Ri are each independently selected from hydrogen, halogen, C1-4 alkyl, C3-6 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, heteroaryl, CN, C(O)Rg, C(O)ORf, or C(O)NRdRd;
wherein said alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl are each optionally substituted by one or more substituents selected from the group consisting of: halogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, aryl, heteroaryl, CN, ORf, SRf, NRdRd, C(O)Rg, C(O)ORf, OC(O)Rg, C(O)NRdRd, NRdC(O)Rg, NRdC(O)NRdRd, OC(O)NRdRd, NRdC(O)ORf, OC(O)ORf, S(O)2NRdRd, NRdS(O)2Rg, and NRdS(O)2NRdRd;
or Rh and Ri together with the carbon atom to which they are attached form a 3- to 8-membered cyclic structure, said cyclic structure optionally containing 0, 1 or 2 heteroatoms selected from N, O, and S, and optionally substituted by one or more substituents selected from the group consisting of halogen, C1-4 alkyl, CN, ORf, SR, NRdRd and =M, wherein M is as defined above; wherein each Rd is independently selected from hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy-C2-4 alkyl, C3-6 cycloalkyl, or 3- to 6-membered heterocyclyl; each Rf is independently selected from hydrogen, C1-4 alkyl, C1-4 haloalkyl, C3-6 cycloalkyl, or 3- to 6-membered heterocyclyl; each Rg is independently selected from hydrogen, C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, aryl, or heteroaryl;
m and n are each independently selected from 0, 1, 2, 3, 4, 5 and 6.

### Claim 12 (depends on 11)

The compound according to claim 11, characterized in that:
M is CRhRi; wherein Rh and Ri are each independently selected from hydrogen, halogen, C1-4 alkyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, aryl, heteroaryl, CN, C(O)Rg, C(O)ORf, and C(O)NRdRd; wherein said alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl are each optionally substituted by one or more substituents selected from the group consisting of halogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, CN, ORf, NRdC(O)Rg, and NRdS(O)2Rg;
wherein Rd, Rf, and Rg are as defined in claim 11;
and wherein m and n are each independently 1 or 2.

### Claim 13 (depends on 1, 2, 12)

The compound according to any one of claims 1-2, characterized in that formula (I) is formula (XIIa) or formula (XIIb):
D, E, and G are each independently selected from N or CH, provided that no more than two of D, E, and G are N;
M, in and n are as defined in claim 12.

### Claim 14 (depends on 1)

The compound according to claim 1, or an optical isomer, pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate or solvate thereof, characterized in that selected from the group consisting of:

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A pharmaceutical composition, characterized in that it comprises a compound according to any one of claims 1 to 14, or an optical isomer, pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate, or solvate thereof, and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

Use of a compound according to any one of claims 1 to 14, or an optical isomer, pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate, or solvate thereof, characterized in that it is for the preparation of a medicament for treating a disease, disorder, or condition associated with CTPS1 activity or expression level.

### Claim 17 (depends on 16)

The use according to claim 16, characterized in that the disease, disorder, or condition is selected from the group consisting of psoriasis, rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis or cutaneous lupus, myasthenia gravis, multiple sclerosis, scleroderma, alopecia areata, inflammatory bowel disease and other various autoimmune diseases; graft-versus-host disease; promotion of vascular smooth muscle cell proliferation and repair after vascular injury or surgery; T-cell lymphoma, B-cell lymphoma, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, angioimmunoblastic T-cell lymphoma, B-cell acute lymphoblastic leukemia, Hodgkin lymphoma, T-cell non-Hodgkin lymphoma (including natural killer/T-cell lymphoma, enteropathy-associated T-cell lymphoma, adult T-cell leukemia/lymphoma, hepatosplenic T-cell lymphoma, and cutaneous T-cell lymphoma), T-cell acute lymphoblastic leukemia, B-cell non-Hodgkin lymphoma (including Burkitt lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma), hairy cell leukemia, lymphoblastic lymphoma, lymphoplasmacytic lymphoma, mucosa-associated lymphoid tissue lymphoma, multiple myeloma, myelodysplastic syndrome, plasma cell myeloma, primary mediastinal large B-cell lymphoma, primary myelofibrosis, essential thrombocythemia, and polycythemia vera and other various hematological cancers.
